W. Ébert
Impact in
- Cancer Research top 5%
- Protease and Inhibitor Mechanisms
- Hematology top 5%
- Blood groups and transfusion
Papers in
-
- Protease and Inhibitor Mechanisms 19
- Oncology 34
- Peptidase Inhibition and Analysis 18
- Lung Cancer Research Studies 11
- Co-authors
- D. Roelcke (15 shared papers)Eberhard Spieß (20 shared papers)Bernd Werle (15 shared papers)Helmut Weicker (15 shared papers)T. Muley (7 shared papers)Thomas Muley (7 shared papers)Hendrik Dienemann (5 shared papers)Tamara T. Lah (9 shared papers)
In The Last Decade
W. Ébert
89 papers receiving 1.8k citations
Peers
Comparison fields: 5 of 115
- Cancer Research 454
- Hematology 283
- Oncology 521
- Immunology and Allergy 81
- Physiology 268
Countries citing papers authored by W. Ébert
This map shows the geographic impact of W. Ébert's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by W. Ébert with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites W. Ébert more than expected).
Fields of papers citing papers by W. Ébert
This network shows the impact of papers produced by W. Ébert. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by W. Ébert. The network helps show where W. Ébert may publish in the future.
Co-authors
The 25 scholars most cited alongside W. Ébert, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 94 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | 2004 | 166 | |
| 2 | CYFRA 21-1 and CEA are independent prognostic factors in 153 operated stage I NSCLC patients. | 2004 | 70 |
| 3 | 1972 | 67 | |
| 4 | Comparison of bone scintigraphy with bone markers in the diagnosis of bone metastasis in lung carcinoma patients. | 2004 | 62 |
| 5 | 1988 | 60 | |
| 6 | 1994 | 56 | |
| 7 | Cathepsin B, plasminogenactivator-inhibitor (PAI-1) and plasminogenactivator-receptor (uPAR) are prognostic factors for patients with non-small cell lung cancer. | 2005 | 54 |
| 8 | 2000 | 53 | |
| 9 | 1997 | 50 | |
| 10 | 1976 | 50 | |
| 11 | 1971 | 47 | |
| 12 | 1995 | 45 | |
| 13 | 1990 | 45 | |
| 14 | 1977 | 44 | |
| 15 | 1969 | 43 | |
| 16 | 1994 | 41 | |
| 17 | 2003 | 40 | |
| 18 | 2006 | 39 | |
| 19 | 2008 | 39 | |
| 20 | Increased CYFRA 21-1 and CEA levels are negative predictors of outcome in p-stage I NSCLC. | 2003 | 38 |
About W. Ébert
W. Ébert is a scholar working on Cancer Research, Oncology, Pulmonary and Respiratory Medicine, Hematology and Molecular Biology, having authored 94 papers that have together received 2.0k indexed citations. Recurring topics across this work include Protease and Inhibitor Mechanisms (19 papers), Peptidase Inhibition and Analysis (18 papers), Glycosylation and Glycoproteins Research (13 papers), Lung Cancer Research Studies (11 papers), Erythrocyte Function and Pathophysiology (10 papers), Blood groups and transfusion (8 papers), Neuroendocrine Tumor Research Advances (8 papers) and Lung Cancer Treatments and Mutations (7 papers). The work is most often cited by research in Cancer Research (454 citations), Hematology (283 citations), Oncology (521 citations), Immunology and Allergy (81 citations) and Physiology (268 citations). W. Ébert has collaborated with scholars based in Germany, Croatia and Slovenia. Frequent co-authors include D. Roelcke, Eberhard Spieß, Bernd Werle, Helmut Weicker, T. Muley, Thomas Muley, Hendrik Dienemann, Tamara T. Lah, H. P. Geisen and Janko Kos. Their work appears in journals such as Vox Sanguinis, Lung Cancer, Chromatographia, Clinical Chemistry and Laboratory Medicine (CCLM) and Journal of Molecular Medicine.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.